Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia (Q33375915)

26 July 2017

Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia (English)

1 reference

chronic lymphocytic leukemia

26 July 2017

0 references

1 reference

1 reference

1 reference

1

Tadeusz Robak

1 reference

26 July 2017

2

Piotr Smolewski

1 reference

PubMed ID

17635235

Olga Grzybowska-Izydorczyk

26 July 2017

series ordinal

4

object named as

Olga Grzybowska-Izydorczyk

1 reference

26 July 2017

5

Jerzy Z Błoński

1 reference

PubMed ID

17635235

26 July 2017

Barbara Cebula-Obrzut

series ordinal

3

object named as

Barbara Cebula

1 reference

26 July 2017

1 August 2007

1 reference

European Journal of Haematology

26 July 2017

1 reference

26 July 2017

79

1 reference

26 July 2017

2

1 reference

26 July 2017

107-113

1 reference

The clinical and epidemiological burden of chronic lymphocytic leukaemia

26 July 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00889.X

Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00889.X

Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00889.X

Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00889.X

Anti-CD20-based therapy of B cell lymphoma: state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00889.X

Monoclonal antibodies in the treatment of chronic lymphoid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00889.X

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00889.X

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00889.X

Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00889.X

Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00889.X

Long-term clinical outcome of B-cell chronic lymphocytic leukaemia patients in clinical remission phase evaluated at phenotypic level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00889.X

Novel immune-based treatment strategies for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00889.X

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00889.X

The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00889.X

Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00889.X

Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00889.X

Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00889.X

Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00889.X

Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00889.X

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00889.X

10.1111/J.1600-0609.2007.00889.X

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference

PubMed ID

17635235